BioIntellisense Stock

BioIntelliSense has announced a continuation of its partnership with UC Davis Health, launching an in-hospital monitoring initiative for patients in need of bone marrow transplants and hematology/oncology services. Using the BioButton wearable device, the programme continuously monitors patients' vital signs, alerting clinicians to subtle shifts that may indicate potential deterioration, enabling faster, more proactive intervention. Early studies have shown that the BioButton improves clinical management of oncology patients. The companies plan to expand the initiative from in-hospital to at-home monitoring.

BioIntelliSense CEO, Dr. Jim Mault, spoke on VatorNews podcast about the company's wearable device, BioButton, that offers continuous physiological monitoring of vital signs. He noted the device's evolution from a consumer wearable to a medical-grade product. The BioButton is designed to help address the shortage of healthcare workers by automating vital sign measurements, thereby reducing the need for bedside checks by nurses.